Schneider Antonius, Faderl Bernhard, Schwarzbach Johannes, Welker Lutz, Karsch-Völk Marlies, Jörres Rudolf A
Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Germany.
Institute of General Practice, University Hospital Klinikum rechts der Isar, Technische Universität München, Germany.
Respir Med. 2014 Jan;108(1):34-40. doi: 10.1016/j.rmed.2013.11.008. Epub 2013 Nov 18.
To compare the prognostic value of FENO with bronchoprovocation testing when the clinical course within the first year after assessment was taken into account; to compare the prognostic values with respect to eosinophilic versus non-eosinophilic inflammatory pattern.
Cross-sectional diagnostic study with a delayed-type reference standard in 393 patients attending a private practice of pneumologists with complaints suspicious of obstructive airway disease.
FENO measurement. Reference standard: ratio FEV1/VC or airway resistance assessed by body plethysmography, with additional bronchoprovocation or bronchodilator testing, as well as spontaneous sputum (smear slides). This was combined with a follow-up evaluation by a structured interview after 12 months.
302 (76.8%) patients were reached for follow-up. Regarding asthma diagnosis, the area under the curve (AUC) for FENO was 0.603 (95%CI 0.528-0.677) for the whole group. With eosinophilic asthma as target, AUC increased (0.819 (95%CI 0.703-0.934)) and exceeded that of bronchoprovocation (0.711 (95%CI 0.584-0.874)). FENO showed no diagnostic value in non-eosinophilic asthma. In patients reporting wheezing and allergic rhinitis at the initial assessment, its positive predictive value was 90.9% (95%CI 62.3%-98.4) at a cut-off of 45 ppb, and 100% (95%CI 56.6-100%) at 81 ppb.
FENO bears limited information when measured non-specifically in primary care, but is useful for diagnosing eosinophilic asthma. If sputum is not available, information on wheezing and rhinitis can narrow down the range of patients in whom FENO is informative. Moreover, the evaluation of the clinical value of FENO benefits from taking into account follow-up data to confirm the diagnosis.
在考虑评估后第一年内的临床病程时,比较呼出一氧化氮(FENO)与支气管激发试验的预后价值;比较嗜酸性粒细胞性与非嗜酸性粒细胞性炎症模式下的预后价值。
对393例因疑似阻塞性气道疾病而到呼吸科私人诊所就诊的患者进行横断面诊断研究,并采用延迟型参考标准。
FENO测量。参考标准:通过体容积描记法评估的第一秒用力呼气容积/肺活量(FEV1/VC)比值或气道阻力,同时进行额外的支气管激发试验或支气管舒张试验,以及自发痰液检查(涂片)。这与12个月后通过结构化访谈进行的随访评估相结合。
302例(76.8%)患者接受了随访。关于哮喘诊断,整个组中FENO的曲线下面积(AUC)为0.603(95%可信区间0.528 - 0.677)。以嗜酸性粒细胞性哮喘为目标时,AUC增加(0.819(95%可信区间0.703 - 0.934)),并超过支气管激发试验的AUC(0.711(95%可信区间0.584 - 0.874))。FENO在非嗜酸性粒细胞性哮喘中无诊断价值。在初始评估时报告有喘息和过敏性鼻炎的患者中,在45 ppb的临界值时其阳性预测值为90.9%(95%可信区间62.3% - 98.4),在81 ppb时为100%(95%可信区间56.6 - 100%)。
在初级保健中进行非特异性测量时,FENO提供的信息有限,但对诊断嗜酸性粒细胞性哮喘有用。如果无法获取痰液,关于喘息和鼻炎的信息可缩小FENO具有诊断价值的患者范围。此外,考虑随访数据以确认诊断有助于评估FENO的临床价值。